Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema.
作者信息
Ratra Dhanashree
机构信息
Department of Vitreoretinal Diseases, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.
出版信息
Indian J Ophthalmol. 2021 Feb;69(2):367-368. doi: 10.4103/ijo.IJO_2611_20.
Abstract
摘要
相似文献
1
Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema.
Indian J Ophthalmol. 2021 Feb;69(2):367-368. doi: 10.4103/ijo.IJO_2611_20.
2
Comparison between the short-term outcomes of bevacizumab and ziv-aflibercept in the treatment of primary diabetic macular oedema.
Acta Ophthalmol. 2017 Dec;95(8):e803-e804. doi: 10.1111/aos.13352. Epub 2017 Jan 13.
3
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.
4
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):83-89. doi: 10.1007/s00417-017-3836-1. Epub 2017 Oct 29.
5
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
Indian J Ophthalmol. 2021 Feb;69(2):360-367. doi: 10.4103/ijo.IJO_459_20.
6
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Ophthalmic Surg Lasers Imaging Retina. 2016 Sep 1;47(9):836-9. doi: 10.3928/23258160-20160901-06.
7
Macular Hole Formation after Intravitreal Injection of Bevacizumab for Diabetic Macular Edema.
Korean J Ophthalmol. 2019 Apr;33(2):198-199. doi: 10.3341/kjo.2018.0079.
8
AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Retina. 2019 Jan;39(1):61-68. doi: 10.1097/IAE.0000000000002253.
9
Impact of Posterior Vitreous Detachment on Treatment Outcomes in Diabetic Macular Edema.
Ophthalmol Retina. 2020 Apr;4(4):452-454. doi: 10.1016/j.oret.2019.12.002. Epub 2019 Dec 9.
10
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
JAMA Ophthalmol. 2016 Aug 1;134(8):888-96. doi: 10.1001/jamaophthalmol.2016.1669.
引用本文的文献
1
Characteristics and Treatment Patterns of Patients with Diabetic Macular Edema Non-Responsive to Anti-Vascular Endothelial Growth Factor Treatment in Ontario, Canada.
Clin Ophthalmol. 2023 Jul 17;17:2013-2025. doi: 10.2147/OPTH.S399981. eCollection 2023.
本文引用的文献
1
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
Indian J Ophthalmol. 2021 Feb;69(2):360-367. doi: 10.4103/ijo.IJO_459_20.
2
Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
Ann Pharmacother. 2020 Aug;54(8):750-756. doi: 10.1177/1060028020904358. Epub 2020 Jan 31.
3
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
Ophthalmologica. 2018;239(4):205-214. doi: 10.1159/000485852. Epub 2018 Feb 2.
4
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27.
5
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12.
6
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18.
7
Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5).
Br J Ophthalmol. 2013 Sep;97(9):1177-80. doi: 10.1136/bjophthalmol-2013-303168. Epub 2013 Jul 3.
8
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
Ophthalmology. 2012 Nov;119(11):2312-8. doi: 10.1016/j.ophtha.2012.08.022. Epub 2012 Sep 19.
9
Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis.
Acta Ophthalmol. 2011 Mar;89(2):e206-7. doi: 10.1111/j.1755-3768.2009.01773.x.
10
Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481.
Zotero 插件